Compare Stocks: NMTR, REVB, SILO, and JAGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JAGX Jaguar Animal Health	$0.60 -14.1%	$1.37	$0.57 ▼ $85.40	$3.08M	-0.07	196,518 shs	2.70 million shs
NMTR 9 Meters Biopharma		$0.00	$0.07 ▼ $6.56	$1.04M	1.36	315,915 shs	N/A
REVB Revelation Biosciences	$1.01 -0.2%	$1.06	$0.88 ▼ $11.60	$4.02M	-0.14	43,186 shs	7,734 shs
SILO Silo Pharma	$2.40 -2.0%	$4.21	$2.20 ▼ $15.15	$3.81M	0.66	150,494 shs	35,479 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JAGX Jaguar Animal Health	-14.06%	-26.31%	-43.43%	-78.69%	-98.99%
NMTR 9 Meters Biopharma	0.00%	0.00%	0.00%	0.00%	+150.00%
REVB Revelation Biosciences	-0.20%	-4.00%	-12.35%	+1.82%	-90.77%
SILO Silo Pharma	-2.04%	-5.51%	-47.94%	-59.32%	-74.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JAGX Jaguar Animal Health	$0.60 -14.1%	$1.37	$0.57 ▼ $85.40	$3.08M	-0.07	196,518 shs	2.70 million shs
NMTR 9 Meters Biopharma		$0.00	$0.07 ▼ $6.56	$1.04M	1.36	315,915 shs	N/A
REVB Revelation Biosciences	$1.01 -0.2%	$1.06	$0.88 ▼ $11.60	$4.02M	-0.14	43,186 shs	7,734 shs
SILO Silo Pharma	$2.40 -2.0%	$4.21	$2.20 ▼ $15.15	$3.81M	0.66	150,494 shs	35,479 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JAGX Jaguar Animal Health	-14.06%	-26.31%	-43.43%	-78.69%	-98.99%
NMTR 9 Meters Biopharma	0.00%	0.00%	0.00%	0.00%	+150.00%
REVB Revelation Biosciences	-0.20%	-4.00%	-12.35%	+1.82%	-90.77%
SILO Silo Pharma	-2.04%	-5.51%	-47.94%	-59.32%	-74.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JAGX Jaguar Animal Health	1.00	Sell	N/A	N/A
NMTR 9 Meters Biopharma	0.00	N/A	N/A	N/A
REVB Revelation Biosciences	1.00	Sell	N/A	N/A
SILO Silo Pharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest NMTR, REVB, SILO, and JAGX Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/25/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/21/2026	SILO Silo Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/28/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/17/2026	JAGX Jaguar Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/9/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/1/2026	SILO Silo Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/18/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
6/11/2026	SILO Silo Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JAGX Jaguar Animal Health	$11.51M	0.27	N/A	N/A	$0.95 per share	0.63
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$0.19 per share	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	$2.53 per share	N/A
SILO Silo Pharma	$70K	54.51	N/A	N/A	$3.08 per share	0.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JAGX Jaguar Animal Health	-$53.43M	-$248.88	N/A	N/A	N/A	-187.88%	N/A	-131.45%	11/12/2026 (Estimated)
NMTR 9 Meters Biopharma	-$43.77M	-$3.46	N/A	N/A	N/A	N/A	-584.97%	-159.45%	N/A
REVB Revelation Biosciences	-$8.91M	-$12.31	N/A	N/A	N/A	N/A	-100.19%	-82.72%	11/5/2026 (Estimated)
SILO Silo Pharma	-$4.23M	-$4.36	N/A	N/A	N/A	-6,726.39%	-81.75%	-66.35%	N/A

Latest NMTR, REVB, SILO, and JAGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	Q2 2026	JAGX Jaguar Animal Health	-$52.15	-$15.70	+$36.45	-$15.70	$4.24 million	$1.23 million
8/13/2026	Q2 2026	SILO Silo Pharma	-$0.32	-$0.76	-$0.44	-$0.76	$0.02 million	N/A
8/6/2026	Q2 2026	REVB Revelation Biosciences	-$0.8750	-$0.87	+$0.0050	-$0.87	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JAGX Jaguar Animal Health	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	N/A
SILO Silo Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JAGX Jaguar Animal Health	0.35	0.69	0.40
NMTR 9 Meters Biopharma	N/A	0.59	0.59
REVB Revelation Biosciences	N/A	6.22	6.22
SILO Silo Pharma	N/A	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JAGX Jaguar Animal Health	12.04%
NMTR 9 Meters Biopharma	22.34%
REVB Revelation Biosciences	12.80%
SILO Silo Pharma	5.58%

Insider Ownership

Company	Insider Ownership
JAGX Jaguar Animal Health	0.18%
NMTR 9 Meters Biopharma	2.40%
REVB Revelation Biosciences	4.80%
SILO Silo Pharma	3.63%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JAGX Jaguar Animal Health	50	5.17 million	5.16 million	No Data
NMTR 9 Meters Biopharma	20	14.34 million	13.99 million	No Data
REVB Revelation Biosciences	10	3.98 million	3.79 million	Not Optionable
SILO Silo Pharma	2	1.59 million	1.53 million	Not Optionable

NMTR, REVB, SILO, and JAGX Headlines

Recent News About These Companies

Silo Pharma (SILO) to Post Quarterly Earnings on Wednesday

August 26, 2026 | americanbankingnews.com

Silo Pharma’s lead asset SPC-15, an intranasal 5-HT4 receptor agonist targeting post-traumatic stress disorder receives Canadian patent

August 20, 2026 | pharmabiz.comP

Silo Pharma Gets Canadian Patent Allowance for Stress Disorder Treatment

August 20, 2026 | finance.yahoo.com

Silo Pharma Acquires Digital Assets via Stock Issuance

August 19, 2026 | tipranks.com

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

August 18, 2026 | globenewswire.com

Silo Pharma Granted European Patent Covering Novel PTSD Therapy

August 10, 2026 | markets.businessinsider.com

Silo Pharma Announces European Patent Grant for SPC-15 PTSD Prevention Therapy

August 10, 2026 | quiverquant.comQ

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform

August 6, 2026 | globenewswire.com

Silo Pharma Advances QwikAgents Commercial Launch and SPC-15 Development

July 21, 2026 | quiverquant.comQ

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

July 21, 2026 | globenewswire.com

Is Silo Pharma, Inc. (SILO) Stock an AI Opportunity After NVIDIA Partnership Boosts QwikAgents Platform?

July 15, 2026 | insidermonkey.com

Silo Pharma’s QwikAgents joins AMD AI developer program to advance AI agent platform

July 14, 2026 | msn.com

Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership

July 14, 2026 | benzinga.com

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

July 14, 2026 | globenewswire.com

CCC Intelligent Solutions, Circle rise premarket; Silo Pharma, Fermi America fall

July 10, 2026 | finance.yahoo.com

Silo Pharma Sinks on Stock Sale

July 10, 2026 | baystreet.ca

Silo Pharma shares slide after announcing up to $11.7 million private placement (SILO)

July 10, 2026 | msn.com

Silo Pharma Announces $4 Million Private Placement with Up to Approximately $7.7 Million in Potential Additional Gross Proceeds from Warrants

July 10, 2026 | quiverquant.comQ

Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

July 10, 2026 | globenewswire.com

Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives

July 7, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR, REVB, SILO, and JAGX Company Descriptions

Jaguar Animal Health NASDAQ:JAGX

$0.60 -0.10 (-14.06%)

As of 09/4/2026 04:00 PM Eastern

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Revelation Biosciences NASDAQ:REVB

$1.01 0.00 (-0.20%)

As of 09/4/2026 03:50 PM Eastern

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Silo Pharma NASDAQ:SILO

$2.40 -0.05 (-2.04%)

As of 09/4/2026 03:59 PM Eastern

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NMTR, REVB, SILO, and JAGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NMTR, REVB, SILO, and JAGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NMTR, REVB, SILO, and JAGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR, REVB, SILO, and JAGX Company Descriptions

Jaguar Animal Health NASDAQ:JAGX

9 Meters Biopharma NASDAQ:NMTR

Revelation Biosciences NASDAQ:REVB

Silo Pharma NASDAQ:SILO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NMTR, REVB, SILO, and JAGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NMTR, REVB, SILO, and JAGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NMTR, REVB, SILO, and JAGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR, REVB, SILO, and JAGX Company Descriptions

Jaguar Animal Health NASDAQ:JAGX

9 Meters Biopharma NASDAQ:NMTR

Revelation Biosciences NASDAQ:REVB

Silo Pharma NASDAQ:SILO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools